Bionics – Year’s Favourites 2022

How we chose our Year’s Favorites

Tubeless insulin pumps, liquid biopsy, and mini-invasive cancer treatments were our top convictions for 2021. Robust clinical data and new partnerships drive acceptance and payer coverage in the right direction. Selected companies are uniquely positioned to maintain significant top and bottom-line growth.

  • We decided to overweight artificial organs, next-generation in-vitro diagnostics, and mini-invasive treatments.
  • Our Year’s Favorites were thus Insulet, Guardant Health, and Novocure.

What did not work

The lack of meaningful clinical updates and the impact of the Covid-19 surge on volumes were the main reasons behind the overall underperformance of the liquid biopsy sector. At the same time, despite encouraging clinical data, mini-invasive technologies for cancer treatment suffered from soft commercial dynamics.

  • Contribution to the Year’s Favorites performance: Novocure -1.41%, Guardant Health -1.16%.

What worked

Tubeless insuline pumps had a very successful year, beating the 2020 revenue mark and growing users, thanks to the release of the artificial pancreas, continued reimbursements, and strong adoption through the pharmacy channel.

  • Contribution to the Year’s Favorites performance: Insulet +0.35%.

This article is available to logged users.
Sign in or request a login.


This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.

As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.

The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.

Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.

It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.

Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.